
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Ryan Cohlhepp, from Takeda Oncology, discusses the accomplishments of the Moving Mountains for Multiple Myeloma team. Cohlhepp, along with other members of the team, were honored at our 2016 Multiple Myeloma Heroes event.
Ryan Cohlhepp, from Takeda Oncology, discusses the accomplishments of the





